Browsing by Subject "Antineoplastic agent"
Now showing items 21-40 of 69
-
Article
-
Article
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up pancreatic cancer
(2005)
-
Article
Essential drugs for cancer chemotherapy
(1994)The WHO recommendation on essential drugs for cancer chemotherapy has been updated. General principles on the proper role of cancer chemotherapeutic agents in relation to efficacy and on the classification of tumours with ...
-
Article
Gastrointestinal stromal tumors during pregnancy: a systematic review of an uncommon but treatable malignancy
(2015)Although modern social structure and medical advances have led to the increasing number of women childbearing in older age, cancer remains a rare diagnosis during pregnancy. There is little given information throughout the ...
-
Article
Interaction pharmacokinetis of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
(2004)Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. Methods: ...
-
Article
Juvenile cancer: Improving care for adolescents and young adults within the frame of medical oncology
(2005)Despite unique tumour epidemiology, a higher cancer incidence and modest survival improvement compared to paediatric patients, adolescents and young adults aged 15-30 have not been considered as a separate, 'special' group ...
-
Article
«Juvenile» oncology - A missing subspecialty. The experience of a reference cancer centre
(2006)Introduction: Despite unique tumor epidemiology and a higher cancer incidence compared to pediatric patients, adolescents and young adults have not been receiving specialized, multidisciplinary, centralized care. In an ...
-
Article
Levels of absolute survival benefit for systemic therapies of advanced cancer: A call for standards
(2003)Research on systemic interventions in patients with advanced stage malignancies should be systematised with an emphasis on the absolute gain in survival for the median patient. Such information is most meaningful with ...
-
Article
Long-term survivors among patients with cancer of unknown primary
(2012)There is a general conception among oncologists that CUP patients behave poorly to treatment and carry a dismal survival. In this paper we are trying to elucidate the different groups of CUP patients and to describe in ...
-
Article
-
Article
Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women
(2006)Introduction. Breast cancer patients developing liver metastases have traditionally been considered to make up a poor prognosis group with median survival rates of less than 6 months. We retrospectively analysed clinicopathologic ...
-
Article
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.
(2010)The article summarizes the expert discussion and recommendations on the use of molecular markers and of biological targeted therapies in metastatic colorectal cancer (mCRC), as well as a proposed treatment decision strategy ...
-
Article
Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group
(2014)Cancer of unknown primary origin (CUP) had a poor prognosis, determined by clinico-histological characteristics, partly due to the lack of insights on its biology. We screened tumour DNA from 87 patients with CUP for CTNNB1 ...
-
Article
Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis
(2005)Background: Interest in the use of preoperative systemic treatment in the management of breast cancer has increased because such neoadjuvant therapy appears to reduce the extent of local surgery required. We compared the ...
-
Article
Noncardiogenic pulmonary edema: An unusual and serious complication of anticancer therapy
(2001)Noncardiogenic pulmonary edema (NCPE) is a rare and less well-recognizable pulmonotoxic syndrome of anticancer therapy than pneumonitis/fibrosis. NCPE is a clinical syndrome characterized by simultaneous presence of severe ...
-
Article
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets
(2012)Cancer of unknown primary sites (CUP) is a compilation of various malignant entities-the majority of which behave aggressively and carry poor prognosis. CUP is classified into two different clinicopathological groups: the ...
-
Article
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site: A hellenic cooperative oncology group study
(1992)Summary: In this retrospective analysis 48 patients with metastatic undifferentiated carcinoma, adenocarcinoma and epidermoid carcimona of unknown origin were studied. The purpose of this analysis was to evaluate both the ...
-
Article
Oxaliplatin (eloxatin™) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma
(2005)Therapeutic options for metastatic insular thyroid carcinoma (ITC) are very limited. We present the case of a 39-year-old woman with refractory metastatic ITC who responded to oxaliplatin plus irinotecan chemotherapy. She ...
-
Article
Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
(1997)A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...
-
Article
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group
(2006)Background: The prognosis of patients with recurrent and/or metastatic head and neck cancer (HNC) is poor. Median survival of these patients following chemotherapy is in the range of 6 to 9 months. In the present randomized ...